7. Nestlé/Galderma

Deal value: $3.6 billion
Deal status: Closed

With serial acquirer Valeant ($VRX) leading the way, the pharma industry has seen plenty of dermatology pickups over the past couple of years--not the least of which has been Nestlé's Galderma buy. With the move, Nestlé took sole possession of a venture it previously shared with L'Oreal--a venture that controlled nearly 7% of the global dermatology market when the companies inked the deal.

Nestlé folded that unit into a new division under its roof, dubbed Nestlé Skin Health SA. There, Galderma's acne and psoriasis treatments joined a host of dermatology products including prescription meds, OTC soaps and sunscreens.

But despite Galderma's market share and brand lineup, growth had been slipping at the time of the deal. Sales expansion had slowed to 3.9%, down from more than 10% in prior years. It'll be up to the Swiss company to use its global marketing muscle to turn that around as it looks to diversify beyond the slumping packaged food business.

For more:
Nestlé plans to use its global marketing juju to rev up Galderma
Pfizer gets $11.85B in nutrition sale to Nestlé
FDA warns Allergan, Galderma on marketing

-- Carly Helfand (email | Twitter)

7. Nestlé/Galderma

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.